Skip to main navigation
Skip to search
Skip to main content
Universidad del Rosario Home
English
Español
Home
Profiles
Research units
Research output
Projects
Press/Media
Datasets
Prizes
Activities
Impacts
Student theses
Search by expertise, name or affiliation
Serious liver disease induced by infliximab
Gabriel J. Tobon
, Carlos Cañas
, Juan Jose Jaller
, Juan Carlos Restrepo
, Juan Manuel Anaya
Research output
:
Contribution to Journal
›
Research Article
›
peer-review
138
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Serious liver disease induced by infliximab'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Liver Disease
100%
Infliximab
100%
Rheumatoid Arthritis
33%
Disease-associated
33%
Rheumatoid Arthritis Patients
33%
Crohn's Disease
33%
Liver Biopsy
33%
Autoimmune
16%
Adverse Reactions
16%
Tumor Necrosis Factor-α
16%
Illicit Drugs
16%
Liver Transplantation
16%
Rheumatologists
16%
Rheumatoid Arthritis Treatment
16%
Hepatocytes
16%
Chronic Inflammation
16%
Autoimmune Hepatitis
16%
Cholestatic Liver Disease
16%
Alcohol Abuse
16%
Liver Injury
16%
Rheumatologic Diseases
16%
Hepatotoxic Drugs
16%
Oral Prednisolone
16%
Hepatic Disease
16%
Complete Recovery
16%
Enucleation
16%
Chimeric Monoclonal Antibody
16%
Aggressive Treatment
16%
Type 1 Criteria
16%
Autoimmune Hepatitis Type 1
16%
Psoriatic Arthritis
16%
Prednisolone
16%
Tumor Necrosis Factor-α Blocker
16%
Hepatic Failure
16%
Collagen Band
16%
Disease Exposure
16%
Illicit Alcohol
16%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Disease
100%
Infliximab
100%
Rheumatoid Arthritis
83%
Inflammatory Arthritis
83%
Autoimmune Hepatitis
33%
Tumor Necrosis Factor
33%
Crohn's Disease
33%
Prednisolone
33%
Adverse Event
16%
Liver Failure
16%
Monoclonal Antibody
16%
Chronic Inflammation
16%
Hepatotoxicity
16%
Liver Injury
16%
Psoriatic Arthritis
16%
Immunology and Microbiology
Infliximab
100%
Inflammatory Arthritis
83%
Tumor Necrosis Factor
33%
Crohn's Disease
33%
Autoimmune Hepatitis
33%
Prednisolone
33%
Autoimmunity
16%
Monoclonal Antibody
16%
Psoriatic Arthritis
16%